Literature DB >> 25322440

Group Sequential Design for Randomized Phase III Trials under the Weibull Model.

Jianrong Wu1, Xiaoping Xiong1.   

Abstract

In this article, a parametric sequential test is proposed under the Weibull model. The proposed test is asymptotically normal with an independent increment structure. The sample size for a fixed sample test is derived for the purpose of group sequential trial design. In addition, a multi-stage group sequential procedure is given under the Weibull model by applying the Brownian motion property of the test statistic and sequential conditional probability ratio test methodology.

Entities:  

Keywords:  Brownian motion; Group sequential trial; Randomized clinical trial; Sample size; Time-to-event; Weibull distribution

Mesh：

Year:  2014        PMID： 25322440      PMCID： PMC4400244          DOI： 10.1080/10543406.2014.971165

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN： 1054-3406            Impact factor:   1.051


  11 in total

1.  Sequential conditional probability ratio tests for normalized test statistic on information time.

Authors:  Xiaoping Xiong; Ming Tan; James Boyett
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.

Authors:  Qingshu Lu; Siu-Keung Tse; Shein-Chung Chow; Min Lin
Journal:  J Biopharm Stat       Date:  2012       Impact factor: 1.051

3.  Power and sample size for survival analysis under the Weibull distribution when the whole lifespan is of interest.

Authors:  M Heo; M S Faith; D B Allison
Journal:  Mech Ageing Dev       Date:  1998-05-01       Impact factor: 5.432

4.  Sample-size formula for the proportional-hazards regression model.

Authors:  D A Schoenfeld
Journal:  Biometrics       Date:  1983-06       Impact factor: 2.571

5.  Group sequential clinical trials with triangular continuation regions.

Authors:  J Whitehead; I Stratton
Journal:  Biometrics       Date:  1983-03       Impact factor: 2.571

6.  Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint.

Authors:  D A Schoenfeld; J R Richter
Journal:  Biometrics       Date:  1982-03       Impact factor: 2.571

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  Repeated assessment of results in clinical trials of cancer treatment.

Authors:  J L Haybittle
Journal:  Br J Radiol       Date:  1971-10       Impact factor: 3.039

9.  Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification.

Authors:  J M Lachin; M A Foulkes
Journal:  Biometrics       Date:  1986-09       Impact factor: 2.571

10.  A practical simulation method to calculate sample size of group sequential trials for time-to-event data under exponential and Weibull distribution.

Authors:  Zhiwei Jiang; Ling Wang; Chanjuan Li; Jielai Xia; Hongxia Jia
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240
View more
  2 in total

1.  Group Sequential Survival Trial Design and Monitoring Using the Log-Rank Test.

Authors:  Jianrong Wu; Xiaoping Xiong
Journal:  Stat Biopharm Res       Date:  2017-03-02       Impact factor: 1.452

2.  Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation.

Authors:  Monika L Metzger; Michael P Link; Amy L Billett; Jamie Flerlage; John T Lucas; Belinda N Mandrell; Matthew J Ehrhardt; Nickhill Bhakta; Torunn I Yock; Alison M Friedmann; Pedro de Alarcon; Sandra Luna-Fineman; Eric Larsen; Sue C Kaste; Barry Shulkin; Zhaohua Lu; Chen Li; Susan M Hiniker; Sarah S Donaldson; Melissa M Hudson; Matthew J Krasin
Journal:  J Clin Oncol       Date:  2021-04-07       Impact factor: 50.717
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.